Aflibercept

CHEMBL1742982 Phase 4 Aprovado Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A protein that works as a trap to capture vascular endothelial growth factor (VEGF), a substance that stimulates abnormal blood vessel growth in conditions like wet macular degeneration and certain cancers. By blocking VEGF, it helps prevent the leaky, abnormal vessels that can damage vision or feed tumor growth.

Áreas Terapêuticas

Mecanismo de Ação

Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A protein that works as a trap to capture vascular endothelial growth factor (VEGF), a substance that stimulates abnormal blood vessel growth in conditions like wet macular degeneration and certain cancers. By blocking VEGF, it helps prevent the leaky, abnormal vessels that can damage vision or feed tumor growth.

Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

Yes, Aflibercept is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1742982. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.